Phase 1
Completed N=69
Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis
Source: ClinicalTrials.gov NCT01262118 ↗Enrolled (actual)
69
Serious AEs
0.0%
Results posted
Jan 2013
Primary outcomePrimary: High-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline — 54.30; 63.43 milligram per deciliter (mg/dL)
Summary
The purpose of study is to explore the effect of CP-690,550 (tasocitinib) on cholesterol metabolism in patients with active rheumatoid arthritis (RA).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY High-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline |
54.30; 63.43 | — |
| PRIMARY High-density Lipoprotein Cholesterol (HDL-C) Concentration at Week 6 |
62.34 | — |
| PRIMARY Cholesterol Ester Production Rate at Baseline |
1.09; 1.11 | — |
| PRIMARY Cholesterol Ester Production Rate at Week 6 |
1.12 | — |
| SECONDARY Low-density Lipoprotein Cholesterol (LDL-C) and Total Cholesterol Concentration |
124.61; 144.88; 193.79; 221.57; 142.68; NA | — |
| SECONDARY Cholesterol Ester Fractional Catabolic Rate |
2.43; 2.17; 2.23; NA | — |
| SECONDARY Low-density Lipoprotein Associated With Apolipoprotein B (LDL-apoB) Production Rate |
0.49; 0.50; 0.52; NA | — |
| SECONDARY Low-density Lipoprotein Associated With Apolipoprotein B (LDL-apoB) Fractional Catabolic Rate |
1.61; 1.50; 1.57; NA | — |
| SECONDARY High-density Lipoprotein Associated With Apolipoprotein A1 (HDL-apoA1) Production Rate |
0.57; 0.59; 0.65; NA | — |
| SECONDARY High-density Lipoprotein Associated With Apolipoprotein A1 (HDL-apoA1) Fractional Catabolic Rate |
1.08; 1.02; 1.11; NA | — |
| SECONDARY Cholesterol Efflux Rate |
4.02; 4.35; 4.04; NA | — |
Eligibility Criteria
Inclusion Criteria
- Males or females, 18 years of age or older with active rheumatoid arthritis; Or male and female healthy volunteers 18 years of age and older
Exclusion Criteria
- Pregnant or lactating women
- Clinically significant systemic disease (other than RA for RA arm)
- Use of lipid-regulating agents
Data sourced from ClinicalTrials.gov (NCT01262118). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.